Quick Answer
Oncotelic Therapeutics, Inc. reported Stockholders Equity of $8.25 million for fiscal year 2024.
Oncotelic Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2024 | $8.25M | -32.0% |
| 2023 | $12.13M | -37.5% |
| 2022 | $19.41M | +144.0% |
| 2021 | $7.96M | -32.4% |
| 2020 | $11.77M | -30.4% |
| 2019 | $16.90M | +585.7% |
| 2018 | $2.46M | +609.7% |
| 2017 | -$483.6K | -103.9% |
| 2016 | $12.50M | -50.7% |
| 2015 | $25.35M | -12.6% |
| 2014 | $29.00M | +380.0% |
| 2013 | $6.04M | +32.9% |
| 2012 | $4.55M | -48.3% |
| 2011 | $8.80M | +267.4% |
| 2010 | -$5.25M | -190.6% |
| 2009 | $5.80M | -79.8% |
| 2008 | $28.74M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $9.05M | +2.2% | +9.0% |
| June 30, 2025 | $8.30M | -31.7% | +3.5% |
| March 31, 2025 | $8.02M | -32.2% | -2.8% |
| December 31, 2024 | $8.25M | -32.0% | -6.8% |
| September 30, 2024 | $8.85M | -29.5% | -27.2% |
| June 30, 2024 | $12.16M | -1.3% | +2.7% |
| March 31, 2024 | $11.83M | -36.9% | -2.4% |
| December 31, 2023 | $12.13M | -37.5% | -3.3% |
- Oncotelic Therapeutics, Inc. showed a decrease of -32.0% in Stockholders Equity compared to the prior fiscal year.
- Over the 2008–2024 period, Oncotelic Therapeutics, Inc.’s stockholders equity has declined by 71.3% (from $28.74 million to $8.25 million).
- The most recent figure is from Oncotelic Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: